Shenzhen Huahong Pharmaceutical

Shenzhen Huahong Marine Biological Medicine Co., Ltd. (commonly known as Huahong Pharmaceutical) is a biotechnology company dedicated to the discovery and development of innovative drugs from marine sources. Established in 2021 as a subsidiary of BGI Marine, the company utilizes BGI's extensive genomics and multi-omics platforms to identify bioactive compounds from marine organisms. Its research pipeline focuses on oncology, metabolic diseases, and rare diseases, with key programs including novel plinabulin derivatives for cancer and selective ALR2 inhibitors for diabetic complications. The company has formed strategic partnerships, such as a major R&D collaboration with Jiangsu Jibeier Pharmaceutical, to accelerate the clinical translation of its marine-derived therapeutic candidates.